AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook or LinkedIn.
Stock Symbol: ABBV
Stock Exchange: NYSE
People. Passion. Possibilities. Those three simple words mean everything at AbbVie, where patients always come first. So do cutting-edge science and innovation, which fuel our expanding pipeline as we take on the world's toughest health challenges in oncology, immunology, liver disease, women's health and beyond. Together, we strive to make a difference for patients around the world. For more visit: www.abbvie.com.
867 articles with AbbVie
-
The FDA is often publishing draft guidelines and asking for expert feedback on that guidance. It’s been a busy week in this regard, with several areas of healthcare and drug development and manufacturing being covered by the agency. Here’s a look.
-
“Humira is an anti-TNF monoclonal antibody that currently treats Crohn's disease, rheumatoid arthritis, ulcerative colitis, hidradenitis suppurativa, psoriasis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis and uveitis,” quotes Humira developer AbbVie’s website. Those...
-
IMBRUVICA® (ibrutinib) Combination Regimen Significantly Improved Survival Versus the Chemoimmunotherapy FCR (Fludarabine, Cyclophosphamide and Rituximab) in Previously Untreated and Younger Chronic Lymphocytic Leukemia (CLL) Patients
12/4/2018
Results from this interim analysis showed ibrutinib plus rituximab prolonged progression-free survival (PFS) compared to a standard chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab (FCR) at nearly 3 years of follow-up (abstract #LBA-4)
-
IMBRUVICA® (ibrutinib) Phase 3 Combination Data with Obinutuzumab Finds Significant Improvement in Progression-Free Survival (PFS) Over Standard Chemoimmunotherapy of Chlorambucil Plus Obinutuzumab
12/3/2018
These data were included in the recent sNDA accepted by the U.S. FDA, which received Priority Review, and could lead to the first chemotherapy-free anti-CD20 combination approved for first-line CLL treatment
-
Noting that from 1998 to 2017 there have been about 146 failed shots at developing drugs for Alzheimer’s disease, PhRMA released a report on the state of the industry. This would not lead most people to think there are many reasons to be optimistic about Alzheimer’s disease research, but the repo...
-
AbbVie Donates $50 Million To St. Jude Children's Research Hospital® To Expand Family-Centered Care
12/3/2018
AbbVie, a research-based global biopharmaceutical company, today announced a historic $50 million donation to St. Jude Children's Research Hospital®
-
IMBRUVICA® (ibrutinib) Data in Chronic Lymphocytic Leukemia (CLL) Show up to Seven Years of Progression-free Survival (PFS) in 80 Percent of Previously Untreated Patients, the Longest Follow-up for a Bruton's Tyrosine Kinase Inhibitor to Date
12/2/2018
With up to seven years of treatment, sustained PFS rates with ibrutinib in CLL/small lymphocytic lymphoma (SLL) at 80 percent for previously untreated patients
-
AbbVie Presents New Data from Phase 3 MURANO Trial of VENCLEXTA®/VENCLYXTO® (venetoclax) in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Who Completed the Fixed Treatment Course
12/1/2018
- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company today presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA® or VENCLYXTO®) in combination with rituximab (VenR).
-
AbbVie Announces HUMIRA® (adalimumab) Global Patent License with Pfizer
11/30/2018
AbbVie announced today patent license agreements with Pfizer over its proposed biosimilar adalimumab product.
-
The American Society of Hematology is holding its 60th Annual Meeting & Exposition starting December 1 and running through December 4 in San Diego. Most of the players, big and small, in cancer drug therapies will be there, presenting updates and breaking stories about their hematology pipelines.
-
Pfizer Reaches a Global Agreement with AbbVie
11/30/2018
Pfizer Inc. today announced that it has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar.
-
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
-
AbbVie could be eyeing another potential billion dollars of annual revenue following the accelerated approval of Venclexta for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older or who cannot tolerate intensive chemotherapy.
-
AbbVie Receives US FDA Accelerated Approval for VENCLEXTA® (venetoclax) for Treatment of Newly-Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy
11/21/2018
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to VENCLEXTA® (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine (LDAC) for the treatment of newly-diagnosed acute myeloid leukemia
-
AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition
11/20/2018
AbbVie will present nearly 40 abstracts featuring data from approved and investigational medicines
-
AbbVie Donates $55 Million to Three Education Nonprofits Supporting Underserved Youth in Chicago & Across America
11/16/2018
AbbVie, a research-based global biopharmaceutical company, today announced a $55 million total donation to three leading nonprofits working to address the achievement gap for children in underserved areas
-
Mission Therapeutics and AbbVie Sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease
11/15/2018
Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities
-
One Busy Week for AbbVie: Hepatitis C, Fibroids, Alzheimer’s & Parkinson’s, and Generic Criticism
11/15/2018
AbbVie presented additional data from two Phase III clinical trials in women with uterine fibroids. In a big news week for the company, what else is AbbVie up to? -
AbbVie Presents Positive Phase 3 Data Demonstrating Investigational Elagolix Reduces Heavy Menstrual Bleeding in Women with Uterine Fibroids at 2018 AAGL Global Congress
11/14/2018
Elagolix, in combination with add-back therapy, achieved statistically significant reduction in heavy menstrual bleeding associated with uterine fibroids compared to placebo
-
Updated: Amgen Co-Founds Fund to Help Conejo Valley Shooting Victims; Donates to Wildfire Victims
11/14/2018
The fund will be administered through the Ventura County Community Foundation. Officials indicate that 100 percent of the funds will go to help victims’ families. The Foundation is calling for additional donations.